|
New guidance from the UK National Diabetes COVID-19 Response Group addresses glucose management in patients with COVID-19 who are receiving dexamethasone therapy. Although there are already guidelines that address inpatient management of steroid-induced hyperglycemia, the authors of the new document say that this new expert opinion paper was needed "given the 'triple insult' of dexamethasone-induced impaired glucose metabolism, COVID-19-induced insulin resistance, and COVID-19 impaired insulin production."
|